Research progress in host-directed anti-tuberculosis drug targets
10.3969/j.issn.1002-2694.2023.00.134
- VernacularTitle:宿主导向的抗结核药物靶点研究进展
- Author:
Xue-Ying GUO
1
;
Zhi-Fang ZHANG
;
Jia-Xu WAN
;
Yan GAO
;
Xiang CHEN
;
Zheng-Zhong XU
;
Xin-An JIAO
Author Information
1. 江苏省人兽共患病重点实验室/江苏省动物重要疫病和人兽共患病防控协同创新中心,扬州大学,扬州 225009
- Keywords:
tuberculosis;
Mycobacterium tuberculosis;
drug target;
immune metabolism;
host-directed therapies
- From:
Chinese Journal of Zoonoses
2023;39(11):1124-1129
- CountryChina
- Language:Chinese
-
Abstract:
Tuberculosis is a serious zoonotic disease causing approximately 10 million new cases worldwide every year.The emergence of various drug-resistant strains of Mycobacterium tuberculosis is currently an important challenge intuberculosispre-vention and control,and an urgent need exists to develop new anti-tuberculosis drugs to treat drug-resistant tuberculosis and shorten the treatment time.The discovery of drug targets is a bottleneck inthe development of new anti-tuberculosis drugs.At present,the widely reported drug targets for tuberculosis include primarily new targets related to the biosynthesis of Mycobac-terium tuberculosis components and immune metabolic pathways.In addition,host-directed therapiestargeting the host immune system have become a research hotspot in recent years.Adjuvant host-directed therapies can enhance the therapeutic effect of tuberculosis and shorten treatment times by affecting granuloma formation,autophagy,host immune metabolism and the intra-cellular killing mechanism,as well as regulating pulmonary inflammation.The discovery of these new targets provides new ide-as for the future development of safe and effective new anti-tuberculosis drugs.
